Trial Profile

WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Artesunate (Primary) ; Imatinib (Primary) ; Infliximab (Primary) ; Remdesivir
Indications SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms SOLIDARITY Finland; SOLIDARITY Plus

Most Recent Events

07 Jun 2023 Planned End Date changed from 30 Jun 2023 to 1 Sep 2023.
15 May 2023 Planned End Date changed from 14 May 2023 to 30 Jun 2023.
15 May 2023 Status changed from completed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com